ASCO2016: HTG Molecular Diagnostics and Cancer Genetics Announce Presentation Of An Immuno-Oncology Study At The American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3–7, 2016 in Chicago, IL.
The study was led by Yu Sunakawa (Showa University Northern Yokohama Hospital, Yokohama, Japan) who contributes to the Japan Clinical Cancer Research Organization (JACCRO) in collaboration with Dr. Heinz-Josef Lenz of the University of Southern California. “We are excited to collaborate with HTG and CGI and get great findings from this important study as it demonstrated that immune-related genes may identify subtypes associated with clinical outcome of 1st-line cetuximab treatment for mCRC,” said Dr. Sunakawa.
Using the HTG EdgeSeq Oncology Biomarker Panel on the HTG EdgeSeq system at CGI, the study investigated the expression levels of immune-related genes implicated in the host immune response to tumors. The
HTG EdgeSeq Oncology Biomarker Panel comprises 2,560 gene probes, using next-generation sequencing (NGS) for quantitative analysis of targeted RNAs.
“We are looking forward to having this new research presented at ASCO, which we believe is an excellent demonstration of the application of NGS-based gene expression in the rapidly developing field of immuno-oncology research,” said TJ Johnson, President and CEO of HTG.
“We are excited that CGI’s immuno-oncology capabilities are able to address the demands of robust research studies that enable personalized medicine by identifying biomarkers to help select cancer patients most likely to benefit from specific therapies,” said Panna Sharma, President and CEO of CGI. “We believe the HTG platform can be a very useful platform for precision oncology diagnostics.”
The poster presentation will be held Monday, June 6, 2016 from 1:00 PM–4:30 PM at the McCormick Place Convention Center, Hall A, during the following session:
Monday, June 6, 2016
Abstract No: 11591
Session: Tumor Biology
Type: Poster Session
Poster Board Number: Poster Session (Board #288)
Full-text version of the abstract is available on http://abstracts.asco.org/176/AbstView_176_165924.html
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with applications of NGS in the immuno-oncology field and usefulness of our platform for precision oncology diagnostics. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop markets for our products and our ability to successfully develop and commercialize diagnostic products. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including, without limitation, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact: Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
About CANCER GENETICS, INC.
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow CGI at:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Contact:
Panna Sharma
President / CEO
Cancer Genetics, Inc.
Phone: 201-528-9200
Email: panna.sharma@cgix.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics, Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” or “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.